The human organoids market is valued at ~USD 1.19 billion in 2024 and will reach USD 2.33 billion by 2029 at a CAGR of 14.4% during the forecast period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures. Their potential in regenerative medicine and disease modeling makes them important for understanding various conditions, ranging from cancer to neurodegenerative disorders. Additionally, the development of technologies, such as 3D bioprinting and imaging; growing public & private investments; industry-academia research collaborations; and regulatory endorsements for organoids as powerful models for research purposes drive their use in various applications across different sectors. Thus, the market for human organoids is expected to continue its steady growth over the next several years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

DRIVER: Growing focus on developing alternatives to animal testing

The demand for alternative animal models for research is one of the major drivers of the global human organoids market. The increasing ethical concerns related to the application of traditional animal testing methods have steered research toward more humane practices. Growing public demand for animal welfare has influenced funding and policy decisions that endorse non-animal research methods. There is a growing demand for research approaches that can yield more relevant and effective responses from humans under different conditions. The biomedical sector, as such, is becoming more encouraging for innovation implemented in the new understandings that expand the market for human organoids.

RESTRAINT: Issues related to incorporating organoids into existing workflows

Organoid integration into already established research workflows presents various challenges that restrain further growth in the market. The primary challenge is the lack of proper infrastructure for 3D cell culture, limiting access to the equipment and techniques required. Organoid manufacturing is very capital and time-intensive; therefore, the adoption of organoids in drug-screening and discovery processes remains low. Developing an organoid requires careful control over morphogenetic signaling pathways and the addition of various growth factors to replicate the in vivo environment, which incurs high costs limiting its use.

OPPORTUNITY: Increasing focus on drug discovery activities

The rapidly growing number of clinical trials drives the human organoids market on an extensive scale by generating an increased demand for innovative models that mimic human physiology. These models let researchers test the efficacy and toxicity of drugs on patient-specific models, thereby providing more precise treatments. Additionally, organoids help improve a comprehensive understanding of complex disease mechanisms and are increasingly accepted by the regulatory department, thus attracting investments from pharmaceutical companies. Consequently, integrating human organoids into clinical trials strongly enhances efficiency and relevance to drug discovery efforts. All these factors promise growth prospects for the human organoids market.

CHALLENGES: Dearth of skilled professionals

The human organoids market faces the challenge of a lack of skilled professionals. Development and work with organoids require large areas of expertise in stem cell biology, tissue engineering, and molecular biology. The lack of expertise naturally slows innovation but also raises costs significantly. Also, there is a significant lack of skilled professionals for making, maintaining, and manipulating such complex structures. Regulation and ethics surrounding organoids also increase the demand for bioethics and compliance experts. Therefore, addressing this shortage will be key to advancing the organoids market and realizing its full potential in healthcare and research.

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Global Human Organoids Market Ecosystem Analysis

The human organoids market ecosystem comprises pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users. Key application segments within the human organoids market are developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, and regenerative medicine. Innovation is primarily driven by collaborations between academia and industry, and growth is further fueled by the increasing demand for personalized medicine.

KEY PLAYERS IN THE HUMAN ORGANOIDS MARKET INCLUDE

• Thermo Fisher Scientific Inc. (US)
• Corning Incorporated (US)
• Merck KGaA (Germany)
• BioIVT (US)
• HUB Organoids BV (Netherlands)

• BICO (Sweden)
• BeCytes Biotechnologies SL (Spain)
• InSphero (Switzerland)
• GBA Group (Germany)
• Kirkstall Ltd. (UK),

• MIMETAS BV (Netherlands)
• Neuromics (US)
• PRIMACYT Cell Culture Technology GmbH (Germany)
• STEMCELL Technologies (Canada)
• ACROBiosystems (China)

In 2023, North America held the largest share of the human organoids market.

The market for human organoids has been segmented into six major geographical regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America holds a major share in the global human organoids market, mainly due to its highly developed healthcare system. This region is superior in terms of medical infrastructure, which enables high research investments. Also, the growing healthcare expenditure indicates the strong commitment of both public and private sectors to fund new therapies and groundbreaking research. The growing number of infections and cancers also creates an important need for good treatment models. Overall, a strong healthcare infrastructure, sufficient financial inputs, and critical public health issues place North America at the forefront of the human organoids market, ensuring continued innovation and application in medical science and personalized medicine.

Recent Developments of Human Organoids Market

• In August 2024, BioIVT (US) acquired ZenBio (US), a key player in advanced cell products and services. The two companies will jointly provide an expanded range of skin-based expertise, primary cell and exosome isolation, and blood products for the pharmaceutical and cosmetics industries.
• In June 2024, Corning Incorporated (US) collaborated with the National Institute for Bioprocessing Research and Training (NIBRT) (Ireland). NIBRT is the center for biopharmaceutical manufacturing research and training. With this collaboration, Corning will place one of its Ascent Fixed Bed Bioreactor (FBR) Systems at NIBRT’s Advanced Therapies building in Dublin, Ireland. This collaboration enhances Corning’s access to the European life sciences market and the rapidly expanding Irish market.
• In July 2024, Merck KGaA (Germany) launched commercial production for its first GMP-compliant cell culture media (CCM) manufacturing line.
• In May 2024, InSphero (Switzerland) collaborated with Genome Biologics (Germany). This partnership will give InSphero exclusive global rights to commercialize Genome Biologics’ groundbreaking 3D Cardiac Organoid Platform. This platform leads in cardiac disease research and provides precise, scalable, and disease-specific organoid models essential for developing new therapeutics.

Content Source:

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

https://www.marketsandmarkets.com/PressReleases/human-liver-model.asp